Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04839809 · ClinicalTrials.gov registry record · Phase 1

A Study to Assess Safety, Tolerability, and Pharmacokinetics of CC-92480 Formulations in Healthy Adult Participants

A Phase 1 study of Healthy Volunteers, sponsored by Celgene.

Completed
Registry status
Phase 1
Development phase
40
Enrollment target
1
Study location

NCT04839809: Completed Phase 1 study of Healthy Volunteers, sponsored by Celgene.

NCT04839809 is a Phase 1 study of Healthy Volunteers that has completed, run by Celgene. The registered enrollment target is 40 participants, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04839809, a Phase 1 study of Healthy Volunteers, has completed, sponsored by Celgene.

COMPLETED
Registry status
Phase 1
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

This is a Phase 1 study that will be conducted in 2 parts. Participants may participate in 1 part only. * Part 1 will be a randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, and PK of CC-92480-02 (Formulation A) administered orally under fasted conditions in healthy adult participants. * Part 2 will be a randomized, open-label, 2 × 4 crossover study (Periods 1, 2, 3, and 4) to evaluate the relative bioavailability (RBA) of Formulation A versus Formulation B under fasted conditions and explore safety, tolerability, and PK effects of food on Formulation A and Formulation B in healthy adult participants.

Primary Outcome

Maximum plasma concentration of drug

Conditions Studied

Interventions

  • OTHER Placebo
  • DRUG CC-92480

Study Locations (1)

Texas

  • PPD Phase 1 Clinic - Austin

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2021-01-19
Est. Completion 2021-10-08
Phase Phase 1
Celgene

308 total trials

What the finished NCT04839809 record still lists

NCT04839809 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (92% lower).

The record links to 1 condition, with Healthy Volunteers appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT04839809 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT04839809 about?

NCT04839809 is a clinical study titled "A Study to Assess Safety, Tolerability, and Pharmacokinetics of CC-92480 Formulations in Healthy Adult Participants". This is a Phase 1 study that will be conducted in 2 parts. Participants may participate in 1 part only. * Part 1 will be a randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, and PK of CC-92480-02 (Formulation A) administered orally under ...

What is the current status of trial NCT04839809?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2021-01-19. Estimated completion is 2021-10-08.

What conditions does trial NCT04839809 study?

This clinical trial studies the following conditions: Healthy Volunteers.

What interventions are being tested in trial NCT04839809?

The interventions under investigation include: Placebo (OTHER), CC-92480 (DRUG).

Who is sponsoring clinical trial NCT04839809?

This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04839809 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Volunteers

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04839809's enrollment target sits among peer trials

40 152nd of 283 higher than 124 of 283 other Healthy Volunteers trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy Volunteers trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04839809, the US trial registry maintained by the National Library of Medicine. NCT04839809 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.